메뉴 건너뛰기




Volumn 7, Issue 1, 2009, Pages 11-19

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: A meta-analysis

Author keywords

Angiogenesis; Gastrointestinal stromal tumor; Sorafenib; Tyrosine kinase inhibitor; Von hippel lindau

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

EID: 65249140606     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.002     Document Type: Review
Times cited : (86)

References (38)
  • 1
    • 78650874372 scopus 로고    scopus 로고
    • Su11248 inhibits kit and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    • Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-478.
    • (2003) Mol. Cancer Ther , vol.2 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3
  • 2
    • 9144274970 scopus 로고    scopus 로고
    • Su11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    • Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20:757-766.
    • (2003) Clin. Exp. Metastasis , vol.20 , pp. 757-766
    • Murray, L.J.1    Abrams, T.J.2    Long, K.R.3
  • 3
    • 0038204144 scopus 로고    scopus 로고
    • Su11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    • O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-3605.
    • (2003) Blood , vol.101 , pp. 3597-3605
    • O'Farrell, A.M.1    Abrams, T.J.2    Yuen, H.A.3
  • 4
    • 12444297983 scopus 로고    scopus 로고
    • The receptor tyrosine kinase inhibitor su11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
    • Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7:225-233.
    • (2004) Angiogenesis , vol.7 , pp. 225-233
    • Osusky, K.L.1    Hallahan, D.E.2    Fu, A.3
  • 6
    • 33644840580 scopus 로고    scopus 로고
    • Targeted therapy for metastatic renal cell carcinoma
    • DOI 10.1038/sj.bjc.6602978, PII 6602978
    • (Pubitemid 43361889) Patel P, Motzer R. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94:614-9.
    • (2006) British Journal of Cancer , vol.94 , Issue.5 , pp. 614-619
    • Patel, P.H.1    Chaganti, R.S.K.2    Motzer, R.J.3
  • 8
    • 38649129787 scopus 로고    scopus 로고
    • New developments in multitargeted therapy for patients with solid tumours
    • DOI 10.1016/j.ctrv.2007.09.003, PII S0305737207001375
    • (Pubitemid 351168610) Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2007; 34:37-48.
    • (2008) Cancer Treatment Reviews , vol.34 , Issue.1 , pp. 37-48
    • Le Tourneau, C.1    Faivre, S.2    Raymond, E.3
  • 9
    • 44449171930 scopus 로고    scopus 로고
    • Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
    • Rosenbaum S, Wu S, Newman M, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16:557-566.
    • (2008) Support Care Cancer , vol.16 , pp. 557-566
    • Rosenbaum, S.1    Wu, S.2    Newman, M.3
  • 11
    • 42449148017 scopus 로고    scopus 로고
    • Sunitinib as second-line treatment for advanced gastric cancer: Preliminary results from a phase II study
    • Abstract 4603
    • Bang Y, Kang Y, Kang W, et al. Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study. J Clin Oncol 2007; 25 (18 suppl) :223s (Abstract 4603).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18
    • Bang, Y.1    Kang, Y.2    Kang, W.3
  • 12
    • 85031340399 scopus 로고    scopus 로고
    • Sutent sunitinib malate, prescribing information: New York, NY: Pfizer;. Available at, Accessed: December 17
    • Sutent (sunitinib malate) [prescribing information]: New York, NY: Pfizer; 2003. Available at: http://www.pfizer.com/pfizer/download/uspi-sutent. pdf. Accessed: December 17, 2008.
    • (2003)
  • 13
    • 34047195479 scopus 로고    scopus 로고
    • Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma
    • Speca J, Yenser S, Creel P, et al. Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer 2006; 5 (suppl 1) :S24-30.
    • (2006) Clin Genitourin Cancer , vol.5 , Issue.1
    • Speca, J.1    Yenser, S.2    Creel, P.3
  • 14
    • 0003575142 scopus 로고    scopus 로고
    • National Cancer Institute: Available at:, Accessed: January 6
    • National Cancer Institute: Common Toxicity Criteria V. Available at: https://webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/welcome-to-ctcae.htm. Accessed: January 6, 2009.
    • (2009) Common Toxicity Criteria V.
  • 17
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
    • (2006) Jama , vol.295 , pp. 2516-2524
    • Motzer, R.J.1    Rini, B.I.2    Bukowski, R.M.3
  • 18
    • 33749505836 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinb in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
    • Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinb in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-1338.
    • (2006) Lancet , vol.368 , pp. 1329-1338
    • Demetri, G.D.1    Van Oosterom, A.T.2    Garrett, C.R.3
  • 19
    • 34648873387 scopus 로고    scopus 로고
    • Sunitinib in metastatic renal cell carcinoma (mRCC) : Preliminary assessment in an expanded access trial with subpopulation analysis
    • Abstract 5010
    • Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC) : preliminary assessment in an expanded access trial with subpopulation analysis. J Clin Oncol 2007; 25 (18 suppl) :237s (Abstract 5010).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18
    • Gore, M.E.1    Porta, C.2    Oudard, S.3
  • 20
    • 36749082718 scopus 로고    scopus 로고
    • Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy
    • Abstract 10022
    • Reichardt P, Kang YK, Ruka W, et al. Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy. J Clin Oncol 2007; 25 (18 suppl) :550s (Abstract 10022).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18
    • Reichardt, P.1    Kang, Y.K.2    Ruka, W.3
  • 21
    • 33750631676 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib malate (SU11248, sutent) in bevacizumab-refractory metastatic renal cell carcinoma
    • Abstract 4522
    • Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248, Sutent) in bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (18 suppl) :222s (Abstract 4522).
    • (2006) J. Clin. Oncol. , vol.24 , Issue.18
    • Rini, B.I.1    George, D.J.2    Michaelson, M.D.3
  • 22
    • 35548945277 scopus 로고    scopus 로고
    • Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma: Updated results
    • Abstract 5040
    • Srinivas S, Roigas J, Gillessen U, et al. Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma: updated results. J Clin Oncol 2007; 25 (18 suppl) :244s (Abstract 5040).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18
    • Srinivas, S.1    Roigas, J.2    Gillessen, U.3
  • 23
    • 36749083833 scopus 로고    scopus 로고
    • Continuous daily dosing of sunitinib malate compares favorably with intermittent dosing in patients with advanced GIST
    • Abstract 10015
    • George S, Blay JY, Casali PG, et al. Continuous daily dosing of sunitinib malate compares favorably with intermittent dosing in patients with advanced GIST. J Clin Oncol 2007; 25 (18 suppl) :548s (Abstract 10015).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18
    • George, S.1    Blay, J.Y.2    Casali, P.G.3
  • 24
    • 38349102230 scopus 로고    scopus 로고
    • Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
    • Chu D, Lacouture M, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncologica 2008; 47:176-186.
    • (2008) Acta. Oncologica. , vol.47 , pp. 176-186
    • Chu, D.1    Lacouture, M.2    Fillos, T.3
  • 26
    • 0033122792 scopus 로고    scopus 로고
    • Capecitabine: Nursing implications of a new oral chemotherapeutic agent
    • Mrozek-Orlowski M, Frye DK, Sandborn HM, et al. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999; 26:753-62.
    • (1999) Oncol. Nurs. Forum. , vol.26 , pp. 753-762
    • Mrozek-Orlowski, M.1    Frye, D.K.2    Sandborn, H.M.3
  • 30
    • 33845313345 scopus 로고    scopus 로고
    • The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
    • DOI 10.1016/j.ejca.2006.09.015, PII S0959804906008483
    • (Pubitemid 44869016) Eskens F, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42:3127-39.
    • (2006) European Journal of Cancer , vol.42 , Issue.18 , pp. 3127-3139
    • Eskens, F.A.L.M.1    Verweij, J.2
  • 31
    • 1442290142 scopus 로고    scopus 로고
    • Combined inhibition of VEGF and pdgf signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms
    • Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18:338-340.
    • (2004) Faseb. J. , vol.18 , pp. 338-340
    • Erber, R.1    Thurnher, A.2    Katsen, A.D.3
  • 32
    • 39049121694 scopus 로고    scopus 로고
    • Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy
    • Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592-596.
    • (2008) Br. J. Dermatol. , vol.158 , pp. 592-596
    • Yang, C.H.1    Lin, W.C.2    Chuang, C.K.3
  • 35
    • 41949099104 scopus 로고    scopus 로고
    • Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study
    • Abstract 9007
    • Lee S, Lee S, Chun Y, et al. Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: results of a randomized double-blind placebo-controlled study. J Clin Oncol 2007; 25 (18 suppl) :494s (Abstract 9007).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18
    • Lee, S.1    Lee, S.2    Chun, Y.3
  • 36
    • 35548991359 scopus 로고    scopus 로고
    • The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)
    • Abstract 5036
    • Stadler WM, Figlin RA, Ernstoff MS, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 2007; 25 (18 suppl) :243s (Abstract 5036).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18
    • Stadler, W.M.1    Figlin, R.A.2    Ernstoff, M.S.3
  • 37
    • 36749078435 scopus 로고    scopus 로고
    • Phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma
    • Abstract 5080
    • Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma. J Clin Oncol 2007; 15 (18 suppl) :254s (Abstract 5080).
    • (2007) J. Clin. Oncol. , vol.15 , Issue.18
    • Gallagher, D.J.1    Milowsky, M.I.2    Gerst, S.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.